CA-TALKDESK
12.3.2024 15:31:31 CET | Business Wire | Press release
Talkdesk®, Inc., a global AI-powered contact center leader for enterprises of all sizes, continues to make it faster and easier for organizations to take advantage of generative artificial intelligence (GenAI) to unlock powerful new efficiencies in the contact center. Accelerating its vision of autonomous customer experience (CX) and building on the recent announcement of Talkdesk Autopilot, the company introduced Talkdesk Autopilot for Healthcare, the next generation of its iconic virtual agent specifically developed to handle patient and member use cases. Talkdesk Autopilot for Healthcare was launched today at the Healthcare Information and Management Systems Society (HIMSS) Global Health Conference and Exhibition.
Talkdesk Autopilot is available across chat and voice channels in the Talkdesk Healthcare Experience Cloud™, the company’s purpose-built platform that helps organizations create synchronized, personalized, and radically convenient experiences for healthcare patients, members, and caregivers. Talkdesk Autopilot for Healthcare supports the whole patient journey through healthcare-specific integrations, workflows, and GenAI models developed based on the company’s extensive experience with healthcare organizations. The result is a connected, intelligent patient and member assistant proficient in resolving consumers’ most common questions and needs.
While many call center automation solutions focus on deflecting callers to other online tools, Talkdesk Autopilot can perform tasks that patients request and seamlessly loop in human agents when necessary. The result is frictionless interactions and improved patient acquisition and loyalty.
Patients and members call or chat with their providers and health plans for many important reasons before and after clinical visits. Talkdesk Autopilot for Healthcare now automates an expanded set of use cases that support the whole patient journey — including new patient acquisition, making and managing appointments, completing PCI-compliant payments, finding a nearby clinic, and managing claims and prior authorizations. In addition to leveraging deep and direct integrations with Electronic Health Record (EHR) systems, the tool now integrates with digital triage and symptom-checking platforms, including Infermedica and Isabel Health. It connects with physician and location directories to help patients find the right provider and directs plan members to the best level of care.
Talkdesk has led the healthcare contact center market since 2021 by directly integrating with EHR systems. Talkdesk Healthcare Experience Cloud is available in the integration marketplaces for leading EHR platforms, including athenahealth, Epic, and Oracle Health (formerly Cerner). Today, Talkdesk announced support for multiple EHR systems for Talkdesk Healthcare Experience Cloud. Now, the purpose-built contact center solution for healthcare can read and update information from different EHRs for customers who may use distinct platforms for various contact centers, specialties, or facilities during a conversation for greater efficiency, accuracy, and personalization.
Supporting Quotes
Tiago Paiva, chief executive officer and founder of Talkdesk, said: “Talkdesk continues to invest in meeting healthcare organizations’ unique and important needs with purpose-built solutions and integrations. Combining the power of GenAI with deep and sophisticated healthcare workflows makes Talkdesk Autopilot for Healthcare a landmark innovation that helps fully resolve, not just deflect, the needs of patients and caregivers throughout their journey. We’re proud to work with great customers every day to deliver a better experience, reduce the burden on human staff, and deliver value to the entire healthcare system.”
Jeff Kaplan, vice president of Patient Access at Memorial Healthcare System, stated: “Our consumers increasingly expect convenience and ease when engaging with their healthcare provider. Talkdesk Autopilot for Healthcare has helped us automate common patient calls and chats, freeing our staff to focus on helping our patients and families with the most complex needs. AI has amazing potential to help healthcare, but it’s critical to partner with vendors who understand the industry and can collaborate to build solutions to fit its unique requirements. We’re excited to continue to innovate with Talkdesk.”
About Talkdesk
Talkdesk® is a global cloud contact center leader for enterprises of all sizes. Talkdesk CX Cloud and Industry Experience Clouds help enterprises deliver modern customer service their way. Our trusted, flexible, and innovative contact center platform leverages AI and automation to drive exceptional outcomes for their customers and improve the bottom line. Serving enterprise customers in over 100 countries, we partner with our customers to deliver continuous innovation and breakthrough results. Our unwavering commitment to doing what we say we will do and our investment in the highest levels of security and reliability for our products make us second to none in the industry. Improve customer experiences, increase efficiency, and grow revenue with Talkdesk, a cloud contact center platform built for your industry. Learn more and take a self-guided demo at www.talkdesk.com.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312839589/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom